AMLX · ISSUER CIK 1658551
Amylyx Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 7 Amylyx Pharmaceuticals, Inc. insiders reported $0.00 of open-market purchases and $3.8M of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$3.8MInsider selling
−$3.8MNet open-market
Oct 7, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 7, 202616:00 | Oct 5, 2026 | AMLX | Director | S · Sell10b5-1 | $27.70 | −30,000 | 782,881 | -4% | −$831K | ||
| Sep 14, 202616:00 | Sep 10, 2026 | AMLX | Chief Medical Officer | S · Sell | $32.40 | −10,028 | 278,064 | -3% | −$325K | ||
| Sep 14, 202616:00 | Sep 10, 2026 | AMLX | Chief Financial Officer | S · Sell | $32.36 | −10,810 | 233,625 | -4% | −$350K | ||
| Sep 14, 202616:00 | Sep 10, 2026 | AMLX | Chief Legal Officer | S · Sell | $32.46 | −9,536 | 190,838 | -5% | −$310K | ||
| Sep 14, 202616:00 | Sep 10, 2026 | AMLX | Co-Chief Executive Officer, Director | S · Sell | $32.18 | −30,464 | 3,613,056 | -1% | −$980K | ||
| Sep 14, 202616:00 | Sep 10, 2026 | AMLX | Co-Chief Executive Officer, Director | S · Sell | $32.19 | −30,464 | 3,613,123 | -1% | −$981K | ||
| Sep 2, 202616:00 | Aug 31, 2026 | AMLX | Director | M · Exercise | $3.41 | +50,000 | 116,900 | +75% | $170K | ||
| Aug 20, 202621:00 | Aug 18, 2026 | AMLX | Chief Financial Officer | A · Grant | — | +22,807 | 244,435 | +10% | — | ||
| Aug 20, 202621:00 | Aug 18, 2026 | AMLX | Co-Chief Executive Officer, Director | A · Grant | — | +60,039 | 3,643,520 | +2% | — | ||
| Aug 20, 202621:00 | Aug 18, 2026 | AMLX | Chief Legal Officer | A · Grant | — | +21,284 | 200,374 | +12% | — | ||
| Aug 20, 202621:00 | Aug 18, 2026 | AMLX | Chief Medical Officer | A · Grant | — | +22,807 | 288,092 | +9% | — | ||
| Aug 20, 202621:00 | Aug 18, 2026 | AMLX | Co-Chief Executive Officer, Director | A · Grant | — | +60,039 | 3,643,587 | +2% | — |